You are here:

  1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Digestive tract conditions
  5. Diarrhoea and vomiting

Bile acid malabsorption: colesevelam

  • Evidence summary
  • Reference number: ESUOM22
  • Published:  29 October 2013
  • Advice
  • Information for the public
Download (PDF)
  • Key points from the evidence
  • Overview for healthcare professionals
  • Relevance to NICE guidance programmes
  • Intervention and alternatives
  • Evidence review: efficacy
  • Evidence review: safety
  • Evidence review: economic issues
  • Evidence strengths and limitations
  • Summary for patients
  • References
  • Development of this evidence summary
  • Appendix: Search strategy and evidence selection
  • About 'Evidence summaries: unlicensed or off-label medicines'

Relevance to NICE guidance programmes

The use of colesevelam for bile acid malabsorption is not appropriate for referral for a NICE technology appraisal and it is not currently planned into any other work programme.

NICE has issued diagnostic guidance on SeHCAT (tauroselcholic [75selenium] acid) for the investigation of diarrhoea due to bile acid malabsorption in people with diarrhoea-predominant irritable bowel syndrome (IBS-D) or Crohn's disease without ileal resection (NICE diagnostics guidanceĀ 7). This recommends SeHCAT for use in research for diagnosing bile malabsorption in these groups.


Next page Intervention and alternatives Previous page Overview for healthcare professionals
Back to top